Chelsea Therapeutics Announces Northera(TM) (Droxidopa) Study 306B Meets Primary Endpoint

[at noodls] – Northeraâ„¢ Demonstrated Statistically Significant Improvement Over Placebo in Reduction of Dizziness/Lightheadedness at Week 1 (p=0.018), the Primary Endpoint, and Standing Blood Pressure at Week 1 (p=0.032), … more

View todays social media effects on CHTP

View the latest stocks trending across Twitter. Click to view dashboard

See who Chelsea is hiring next, click here to view